TVRD vs ASTI Comparison

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Ascent Solar Technologies Inc is a solar technology company that manufactures and sells photovoltaic (PV) solar modules that are flexible, durable, and possess attractive power to weight and power to area performance. Its technology provides renewable power solutions to high-value production and specialty solar markets where traditional rigid solar panels are not suitable, including space power beaming, aerospace, satellites, near earth orbiting vehicles, fixed wing unmanned aerial vehicles (UAV), aquatic, terrestrial, and other weight-sensitive markets with transformational high quality, value added product applications. It operates in single PV segment that sells PV products and engineering services and currently, is selling it in North America.